However, directly targeting the nucleus-located HIF-1 (α and β dimer) has proven to be challenging and so far few HIF-1 inhibitors have progressed through clinical development, raising the question of whether HIF-1 is a legitimate pharmacological target in those cancer patients6, 7, 8, 9, 10. Here, HIF1A is linked to cancer.